The objective of the study is to evaluate the long-term safety and efficacy of a sub-retinal injection of BIIB111 in participants with Choroideremia (CHM) who have been previously treated with BIIB111 and who have exited an antecedent study; these treated participants will be compared with untreated control participants who have exited the STAR (NCT03496012) study and BIIB112 in participants with X-linked retinitis pigmentosa (XLRP) who have been previously treated with BIIB112 and who have exited an antecedent study.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Percentage of Participants with Adverse Events (AEs)
Timeframe: Up to 5 years
Ophthalmic Examination Assessment: Intraocular Pressure (IOP)
Timeframe: Up to 5 years
Ophthalmic Examination Assessment: Abnormal Slit Lamp Examination
Timeframe: Up to 5 years
Ophthalmic Examination Assessment: Lens Opacity Grading
Timeframe: Up to 5 years
Ophthalmic Examination Assessment: Anterior Chamber and Vitreous Inflammation
Timeframe: Up to 5 years
Ophthalmic Examination Assessment: Indirect Ophthalmoscopy
Timeframe: Up to 5 years